prevalence of sars cov 2 infection and sars cov 2 specific antibody detection among CORD-Papers-2022-06-02 (Version 1)

Title: Prevalence of SARS-CoV-2 infection and SARS-CoV-2-specific antibody detection among health care workers and hospital staff of a university hospital in Colombia
Abstract: Objective : This study aims to determine current and previous SARS-COV-2 infection and describe risk factors associated with seropositivity among HCWs between June and October of 2020. Methodology : We analyzed data from the day of enrollment of a prospective cohort study to determine point prevalence and seroprevalence of SARS-CoV-2 infection in HCWs of a university hospital in Colombia. We collected respiratory samples to perform RT-PCR tests and blood samples to measure SARS-CoV-2 IgM and IgG antibodies. We collected and analyzed data on nosocomial and community risk factors for infection. Findings : 420 hospital staff members were included. The seroprevalence at baseline was 232%. Of which 107% had only IgM 07% had IgG and 117% had IgM and IgG antibodies. The prevalence of acute SARS-CoV-2 infection was 19%. Being a nurse assistant was significantly associated with seropositivity compared with all other job duties (PR 239 95%CI: 127 - 365 p=001). Conclusions : Overall SARS-CoV-2 prevalence was 19% and seroprevalence was 2315%. Nurse assistants medical doctors or students and laboratory workers had a higher possibility of being SARS-CoV-2 seropositive.
Published: 2022-03-23
Journal: IJID Regions
DOI: 10.1016/j.ijregi.2022.03.013
DOI_URL: http://doi.org/10.1016/j.ijregi.2022.03.013
Author Name: Caballero Nohem
Author link: https://covid19-data.nist.gov/pid/rest/local/author/caballero_nohem
Author Name: Nieto Mara A
Author link: https://covid19-data.nist.gov/pid/rest/local/author/nieto_mara_a
Author Name: Suarez Zamora David A
Author link: https://covid19-data.nist.gov/pid/rest/local/author/suarez_zamora_david_a
Author Name: Moreno Sergio
Author link: https://covid19-data.nist.gov/pid/rest/local/author/moreno_sergio
Author Name: Remolina Camila I
Author link: https://covid19-data.nist.gov/pid/rest/local/author/remolina_camila_i
Author Name: Duran Daniela
Author link: https://covid19-data.nist.gov/pid/rest/local/author/duran_daniela
Author Name: Vega Daniela
Author link: https://covid19-data.nist.gov/pid/rest/local/author/vega_daniela
Author Name: Rodrguez Urrego Paula A
Author link: https://covid19-data.nist.gov/pid/rest/local/author/rodrguez_urrego_paula_a
Author Name: Gmez Claudia P
Author link: https://covid19-data.nist.gov/pid/rest/local/author/gmez_claudia_p
Author Name: Rojas Diana P
Author link: https://covid19-data.nist.gov/pid/rest/local/author/rojas_diana_p
Author Name: Ramrez Andrea
Author link: https://covid19-data.nist.gov/pid/rest/local/author/ramrez_andrea
Author Name: Martnez Oscar
Author link: https://covid19-data.nist.gov/pid/rest/local/author/martnez_oscar
Author Name: Baldin Elorza Ana M
Author link: https://covid19-data.nist.gov/pid/rest/local/author/baldin_elorza_ana_m
Author Name: Hernndez Luis J
Author link: https://covid19-data.nist.gov/pid/rest/local/author/hernndez_luis_j
Author Name: Quintero Juliana
Author link: https://covid19-data.nist.gov/pid/rest/local/author/quintero_juliana
sha: 42fb27f85932b400880fe21ae5899134ce3a4b60
license: els-covid
license_url: https://www.elsevier.com/about/policies/open-access-licenses/elsevier-user-license
source_x: Elsevier; PMC; WHO
source_x_url: https://www.elsevier.com/https://www.ncbi.nlm.nih.gov/pubmed/https://www.who.int/
pmcid: PMC8942465
pmcid_url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942465
url: https://doi.org/10.1016/j.ijregi.2022.03.013 https://api.elsevier.com/content/article/pii/S277270762200042X https://www.sciencedirect.com/science/article/pii/S277270762200042X?v=s5
has_full_text: TRUE
Keywords Extracted from Text Content: https://doi Colombia Elsevier centre COVID-19 SARS-CoV-2-specific antibody IJID SARS-CoV-2 HCWs serum PPE COVID-19 upper arm IgM antibody Cardiac μL Carrasquilla-Barrera, 2021) Colombia nasopharyngeal samples nasopharyngeal U-Mann confirmar su primer caso Coronavirus-2 blood CoVIDA SARS-CoV-2 nasopharyngeal IgM. trimester low-exposure wards SeroTracker P<0·05 95%CI:0·17-1·07 women Abeya wall Blood Ruiz-Gómez Bucaramanga Metropolitan Area Oxygen SARS-CoV-2 antibodies IgG antibodies writing-review IPC Fundación Santa people cellular Google-News Rnasa IgM COVID-19 risk factors questionnaire patient SARS-CoV-2 IgM/IgG Antibody Rapid Test Coronavirus Disease 2019 9·8 B LFA throat patients 1·26-3·65 blood samples SARS-CoV-2 IgG SARS-CoV-2 human Bogotá IgM-/IgG+ SARS-CoV-2 IgM participants human serum ORF1ab Figure 2 . Wuhan, Blood samples SARS-CoV-2 IgM/IgG antibody Sandal SARS-COV-2 Fundación 95·30 -100·00%](SEASUN BIOMATERIALS IgM antibodies IgG Biotechnology men blood/serum/plasma COVID-19 Vacunómetro | SALUDATA linktest 86·68
Extracted Text Content in Record: First 5000 Characters:publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Prevalence of SARS-CoV-2 infection and SARS-CoV-2-specific antibody detection among health care workers and hospital staff of a university hospital in Colombia ) , Prevalence of SARS-CoV-2 infection and SARS-CoV-2-specific antibody detection among health care workers and hospital staff of a university hospital in Colombia, IJID Regions (2022), doi: https://doi. The Coronavirus Disease 2019 (COVID-19) pandemic started as a cluster of pneumonia cases in Wuhan, China, in December 2019 (Salata et al., 2019) . A few weeks later, the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19, was identified, and China shared the genetic sequence on January 12th, 2020 (WHO, n.d.) . In March 2020, the World Health Organization (WHO) declared a global pandemic, and a year later, there were more than 147 million cases reported and more than 3 million deaths due to COVID-19 across the world (Google-News, n.d.) . In Colombia, the first COVID-19 case was reported in March 2020. Since then, three waves have occurred (Vista de COVID-19 en Colombia: un año después de confirmar su primer caso, n.d.; World Health Organization (WHO), n.d.). Until July 24th, 2021, 24,186 accumulated cases of confirmed COVID-19 in healthcare workers (HCWs) have been reported in Bogotá, corresponding to 1·7% of all COVID-19 cases in the city Trabajadores salud | SALUDATA, n.d.). Evidence supports that HCWs have a higher risk of infection by SARS-CoV-2 due to their direct contact with patients (Grant et al., 2021) . They also might have a higher risk of severe infection, as it is presumed that the risk of mortality is higher on those who acquired the infection through nosocomial transmission than those with community transmission (Wang et al., 2020) . Multiple risk factors have been associated with COVID-19 infection in HCWs, including lack of personal protective equipment, workplace setting, profession, and increased exposure to the virus (Gholami et al., 2021) . Epidemiological surveillance is fundamental to monitor the pandemic and formulate immediate and long-term strategies to mitigate its burden. The screening of asymptomatic HCWs allows early detection of infection and aims to reduce the rate of transmission to patients and colleagues. Thus, this study aimed to determine recent and previous SARS-COV-2 infection and describe the risk factors associated with SARS-CoV-2 infection among active workers of a University Hospital in Bogotá, Colombia, during the COVID-19 pandemic between June and October of 2020. This time frame included part of the first wave of the SARS-CoV-2 in the country, which occurred between July and August of 2020 ( Figure 1 ). We conducted this study in a University Hospital that provides high complexity, timely, and top-quality certified services to patients in Bogotá, Colombia, with over 3,000 employees. The Hospital has specific COVID-19 emergency room, hospitalization, and intensive care unit (ICU) beds and is a referral hospital in the city for COVID-19 medical attention. Bogotá is the capital of Colombia, and has a population of 7.834.167 inhabitants. The city is divided into 20 localities, one of them is Usaquén, where the University Hospital is located, and the first case of COVID-19 in Colombia was detected. We conducted a prospective cohort study, as part of the CoVIDA project (Ruiz-Gómez and Carrasquilla-Barrera, 2021), an initiative for active epidemiological surveillance in Bogotá, Colombia (Amendola et al., 2020; Varela et al., 2021) . In this study, we proposed a testing scheme for respiratory and blood sampling according to the RT-PCR results of participants at baseline. (See supplementary material 2) All active workers regardless of their risk of SARS-CoV-2 exposure were invited to voluntarily participate, via institutional e-mail, in a 6-month study to assess the impact of SARS-CoV-2 infection in the hospital. Here we analyzed only data from the day of enrollment of each participant to determine point prevalence and seroprevalence of SARS-CoV-2 infection. Individuals who desired to participate and met the eligibility criteria were assigned an appointment to join the study. The inclusion criteria included: 1) women and men older than 18 years and 2) active hospital workers. We excluded participants with contraindications for collecting nasopharyngeal and blood samples. We recruited participants between June 25th and October 30th of 2020 ( Figure 1 ). On the first visit, we obtained informed consent, performed a medical evaluation, and recorded weight, height, and vital signs from all participants. Then, we applied a risk factor questionnaire for nosocomial and community SARS
PDF JSON Files: document_parses/pdf_json/42fb27f85932b400880fe21ae5899134ce3a4b60.json
G_ID: prevalence_of_sars_cov_2_infection_and_sars_cov_2_specific_antibody_detection_among